WebCytokinetics develops muscle activators and muscle inhibitors to improve muscle function in patients with cardiovascular and neuromuscular diseases. [3] [4] In 2004 the company … WebApr 13, 2024 · The projected fair value for Cytokinetics is US$38.04 based on 2 Stage Free Cash Flow to Equity. Cytokinetics' US$34.05 share price indicates it is trading at similar levels as its fair value estimate
Did you know?
WebMar 31, 2024 · Cytokinetics’ ALS research has revolved around “troponin,” a protein involved in muscle movement, with the idea being that activating this protein may help treat the disease. The company’s first attempt at this resulted in an experimental medicine called tirasemtiv, but it was shelved after missing the primary goal of a late-stage study ... WebApr 12, 2024 · Cytokinetics, Incorporated has a 1 year low of $32.96 and a 1 year high of $55.80. Cytokinetics (NASDAQ:CYTK – Get Rating) last posted its earnings results on Wednesday, March 1st. The ...
WebCytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, ... In January 2007, Cytokinetics named Robert I. Blum as president and CEO. Prior to this, Blum has been involved in the company since its founding, ... WebMar 31, 2024 · The company in the coming months will assess measures needed for the development of its neuromuscular pipeline, Cytokinetics CEO Robert Blum said in a statement. ALS, also known as Lou Gehrig’s disease, breaks down nerve cells in the brain and spinal cord that make muscles work, leading to progressive paralysis and death.
Web2 days ago · Cytokinetics will seek international approval for drug following FDA rejection, says CEO Robert Blum Cytokinetics President and CEO Robert Blum joins 'Power Lunch' to discuss the FDA's rejection of the company's heart failure drug, how FDA approval increases shareholder value and future treatment pla... WebMay 7, 2024 · Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Diane Weiser – Senior Vice …
WebAug 12, 2024 · Cytokinetics CEO Robert Blum on Biopharma Outlook Daybreak Asia TV Shows August 12th, 2024, 1:08 PM PDT Robert Blum, President and CEO at …
WebApr 13, 2024 · In other Cytokinetics news, CEO Robert I. Blum sold 12,500 shares of the company’s stock in a transaction on Tuesday, March 28th. The stock was sold at an average price of $35.05, for a total transaction of $438,125.00. Following the completion of the sale, the chief executive officer now owns 441,058 shares in the company, valued at ... china on the brink of collapseWebFeb 21, 2024 · The estimated net worth of Robert I. Blum is at least $17.05 million as of January 17th, 2024. Mr. Blum owns 406,412 shares of Cytokinetics stock worth more than $17,048,983 as of March 4th. This net worth evaluation does not reflect any other investments that Mr. Blum may own. Learn More about Robert I. Blum's net worth. china on the map of the worldWebCytokinetics's President, Chief Executive Officer and Director is Robert I Blum. Other executives include Daniel R Casper, Vice President, Information Technology; Andrew … gram and dun brunch menuWebMar 31, 2024 · Cytokinetics Diane Weiser Senior Vice President, Corporate Communications, Investor Relations (415) 290-7757 Source: Cytokinetics, Incorporated … china on the map imagesWebMar 31, 2024 · The company in the coming months will assess measures needed for the development of its neuromuscular pipeline, Cytokinetics CEO Robert Blum said in a statement. ALS, also known as Lou Gehrig’s disease, breaks down nerve cells in the brain and spinal cord that make muscles work, leading to progressive paralysis and death. ... gram and ounce conversionWebJan 2024 - Mar 20243 years 3 months. San Francisco Bay Area. Accountable for leading Development Operations to ensure timely … china on the mapWebDec 27, 2024 · Cytokinetics has been finding treatments for muscle weakening conditions such as ALS for 20 years. President and CEO … china on thayer